ENTRY       D04477                      Drug
NAME        Insulin lispro (USP/INN);
            Insulin lispro (genetical recombination) (JAN);
            Insulin lispro (genetical recombination) [Insulin lispro Biosimilar 1] (JAN);
            Insulin lispro-aabc;
            Humalog (TN);
            Lyumjev (TN)
PRODUCT     ADMELOG (Sanofi-Aventis U.S. LLC)
            HUMALOG (A-S Medication Solutions)
            HUMALOG (Eli Lilly and Company)
            HUMALOG (Eli Lilly and Company)
            HUMALOG (Eli Lilly and Company)
            INSULIN LISPRO (A-S Medication Solutions)
            INSULIN LISPRO (Eli Lilly and Company)
            INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION (Eli Lilly and Company)
            LYUMJEV (Eli Lilly and Company)
FORMULA     C257H383N65O77S6
EXACT_MASS  5803.6376
MOL_WEIGHT  5807.5702
SEQUENCE    (A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
            Gln Leu Glu Asn Tyr Cys Asn
            (B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
            Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Lys Pro Thr
            (Disulfide bridge: A6-A11, A7-B7, A20-B19)
  TYPE      Peptide
CLASS       Antidiabetic agent
             DG01636  Insulin preparation
              DG01796  Insulin analog, fast-acting
            Metabolizing enzyme inducer
             DG01637  CYP1A2 inducer
REMARK      Therapeutic category: 2492
            ATC code: A10AB04 A10AC04 A10AD04
            Product: D04477<JP/US>
EFFICACY    Antidiabetic, Insulin receptor agonist
  DISEASE   Diabetes mellitus [DS:H00408 H00409]
COMMENT     Insulin analog
TARGET      INSR (CD220) [HSA:3643] [KO:K04527]
  PATHWAY   hsa04910(3643)  Insulin signaling pathway
            hsa04930(3643)  Type II diabetes mellitus
INTERACTION CYP induction: CYP1A2 [HSA:1544]
STR_MAP     map07051  Antidiabetics
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10A INSULINS AND ANALOGUES
                A10AB Insulins and analogues for injection, fast-acting
                 A10AB04 Insulin lispro
                  D04477  Insulin lispro (USP/INN) &lt;JP/US&gt;
                A10AC Insulins and analogues for injection, intermediate-acting
                 A10AC04 Insulin lispro
                  D04477  Insulin lispro (USP/INN) &lt;JP/US&gt;
                A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
                 A10AD04 Insulin lispro
                  D04477  Insulin lispro (USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Insulins
               Insulin, Rapid-acting
                Insulin Lispro
                 D04477  Insulin lispro (USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              24  Hormones
               249  Miscellaneous
                2492  Pancreatic hormones
                 D04477  Insulin lispro (USP/INN); Insulin lispro (genetical recombination) (JAN); Insulin lispro (genetical recombination) [Insulin lispro Biosimilar 1] (JAN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG01636  Insulin preparation
               DG01796  Insulin analog, fast-acting
                D04477  Insulin lispro
             Metabolizing enzyme inducer
              DG01637  CYP1A2 inducer
               D04477  Insulin lispro
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG01636  Insulin preparation
               D04477  Insulin lispro
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               INSR family
                INSR (CD220)
                 D04477  Insulin lispro (USP/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04477
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D04477
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D04477
DBLINKS     CAS: 133107-64-9
            PubChem: 17398123
///
